Compare BKTI & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKTI | TENX |
|---|---|---|
| Founded | 1997 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.9M | 317.8M |
| IPO Year | 2000 | 2001 |
| Metric | BKTI | TENX |
|---|---|---|
| Price | $83.74 | $13.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $74.00 | $29.67 |
| AVG Volume (30 Days) | 37.6K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.89 | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $74,094,000.00 | N/A |
| Revenue This Year | $6.57 | N/A |
| Revenue Next Year | $15.00 | N/A |
| P/E Ratio | $119.27 | ★ N/A |
| Revenue Growth | ★ 45.42 | N/A |
| 52 Week Low | $36.17 | $5.67 |
| 52 Week High | $104.55 | $18.38 |
| Indicator | BKTI | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 54.77 | 64.01 |
| Support Level | $76.11 | $13.16 |
| Resistance Level | $85.90 | $14.15 |
| Average True Range (ATR) | 3.14 | 0.81 |
| MACD | 0.50 | 0.31 |
| Stochastic Oscillator | 86.81 | 91.71 |
BK Technologies Corp is a holding company that, through BK Technologies, Inc., its operating subsidiary, provides public safety-grade communications products and services designed to make first responders safer and more efficient. All operating activities described herein are undertaken by its operating subsidiary. The Company has one reportable segment - Land Mobile Radio (LMR) Products and Solutions. The LMR segment provides radio devices that are hand-held (portable) or installed in vehicles (mobile) and operate on private radio systems that are P25 compliant. The Company derives revenue in North America and manages the business activities on a consolidated basis.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.